- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00914615
Stereotactic Body Radiation Therapy (SBRT) in Liver Metastasis (COLD 3)
Phase II Trial of Stereotactic Body Radiation Therapy for Unresectable Liver Metastases From Colorectal Carcinoma
This study is designed to see whether stereotactic body radiation therapy (SBRT) can reduce tumour size, slow progression of the disease, prolong life and improve quality of life. SBRT is concentrated focused radiation therapy delivered very precisely to the liver tumour.
Presently, the treatment for unresectable liver metastases from colorectal cancer is most often chemotherapy or novel targeted therapy. These treatments may improve survival, but not control the metastases permanently; so new treatments are needed to control metastases. It is hoped that knowledge obtained from this study will improve our ability to treat patients with liver tumours that cannot be treated with surgery and other methods, and that SBRT may prove to be a treatment that can lead to long-term and permanent control of liver tumours for some patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network, Princess Margaret Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligible patients must have liver metastases from colorectal cancer 1) with histologic confirmation of metastases, 2) histologic confirmation of primary cancer and multiple new enhancing lesions in the liver consistent with metastases, or 3) histologic confirmation of primary cancer and a growing enhancing lesion in the liver Phase II SBRT Mets 13 consistent with a metastases
- Either 1) the tumour must be unresectable, based on the opinion of an experienced surgeon specializing in hepatic resection, or 2) the patient must be medically inoperable, or 3) extra-hepatic metastases must be present (making hepatic surgery an inappropriate treatment option).
- Karnofsky performance status (KPS) > 60 (Appendix II)
- Age: 18 years or older. Both male & female patients of all races can be included in this study. Female patients within reproductive years may not be, nor become, pregnant during participation in this study
- Patients must have recovered from the effects of previous therapy
- Maximal tumor size of 15 cm
Adequate organ function as assessed as follows:
- Hemoglobin > 90 g/L
- Absolute neutrophil count > 1.0 bil/L
- Platelets > 60bil/L
- Bilirubin < 4.0 times upper range of normal
- INR < 1.5 or correctable with vitamin K (unless patients are on anticoagulation doses that have been stable for the past 2 months and they haven't had a bleed in the past 2 months)
- AST or ALT < 6.0 times upper limit of normal range
- Child's A 5-6 liver score
- Previous liver resection or ablative therapy is permitted
- Life expectancy > 3 months
- The volume of uninvolved must be at least 700 cc
- Up to five discrete liver tumors
- Patients must have signed a study-specific informed consent form. If the patient's mental status precludes this, written informed consent may be given by the patient's legal representative.
Exclusion Criteria:
- Patients with active hepatitis or encephalopathy related to liver failure
- Prior radiation therapy to the right upper abdomen, precluding reirradiation of the liver. That is, any previous radiation therapy in which a mean dose to the liver of 15 Gy in conventional fractionation was delivered, or previous doses to critical normal structures that would make re-irradiation unsafe. The PI should be called if there is any question of safety of re-irradiation.
- Prior uncontrolled, life threatening malignancy within the six months.
- Pregnancy is not permitted, and in women of child bearing age, a pregnancy test and acceptable methods of contraception are warranted.
- Previous variceal bleed within the past 2 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SBRT for liver mets from colorectal cancer
|
Radiation therapy will be delivered on six occasions, over two weeks.
Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures).
You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.
Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria.
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 5 years
|
5 years
|
Quality of life
Time Frame: 5 years
|
5 years
|
Overall progression free survival
Time Frame: 5 years
|
5 years
|
CTC3.0 toxicity
Time Frame: 5 years
|
5 years
|
Cytokine response to radiation and association with complications
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UHN REB 07-0348-C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Metastasis
-
McGill University Health Centre/Research Institute...RecruitingLiver Dysfunction | Liver Metastasis Colon Cancer | Liver RegenerationCanada
-
Asklepios Kliniken Hamburg GmbHCompletedColon Cancer Liver Metastasis | Contrast Enhances Intraoperative Ultrasound | Imaging for Liver Cancer | Imaging for Liver MetastasisGermany
-
UMC UtrechtCompletedLiver Tumors | Liver MetastasisNetherlands
-
Western University, CanadaNot yet recruitingNAFLD | Liver Metastasis Colon Cancer | Liver Steatoses
-
Fudan UniversityRecruiting
-
Hospital Universitario Virgen de la ArrixacaCompletedColorectal Liver Metastasis | Laparoscopic Liver ResectionSpain
-
Rigshospitalet, DenmarkActive, not recruitingColorectal Liver MetastasisDenmark
-
RWTH Aachen UniversityTerminatedLiver MetastasisGermany
-
University of Wisconsin, MadisonWithdrawnLiver Metastasis Colon CancerUnited States
-
Odense University HospitalUnknownLiver Metastasis Colon CancerDenmark
Clinical Trials on Stereotactic Body Radiation
-
Indiana University School of MedicineUniversity of Colorado, DenverCompletedCarcinoma, HepatocellularUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Cancer Prevention Research Institute of TexasActive, not recruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Malignant Neoplasms of Urinary Tract | Oligometastatic Renal Cell CarcinomaUnited States
-
Roswell Park Cancer InstituteCompletedLung CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedPain | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedLung CancerUnited States, Canada
-
Fox Chase Cancer CenterRecruitingMalignant Neoplasm of Stomach | Neoplasm - Soft Tissue Pelvis Malignant SecondaryUnited States
-
Barts & The London NHS TrustBarts Cardiovascular CTU (Queen Mary University of London)Not yet recruitingHypertrophic CardiomyopathyUnited Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Recruiting
-
Erasmus Medical CenterCompletedKlatskin TumorNetherlands
-
Paul W. Read, MDUnknownMetastatic Bone LesionUnited States